News
-
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research updates BUY recommendation and USD 7.50 price target for Cardiol Therapeutics Inc. Expansion of Phase III MAVERIC trial network in the US signifies credibility and potential value growth -
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research updates BUY recommendation for Cardiol Therapeutics Inc to USD 7.50 target price due to recent corporate updates and pipeline progress, including MAVERIC trial advancements -
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research updates BUY recommendation for Cardiol Therapeutics Inc., lowering price target to USD 7.80 based on positive Phase II ARCHER data on CardiolRx for acute myocarditis -